Journal
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY
Volume 10, Issue -, Pages -Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/2045125320954992
Keywords
cannabidiol; CBD; cannabis oil; over the counter; health supplement; safety; efficacy
Categories
Funding
- National Institute for Health Research Doctoral Research Fellowship [300273]
- Senior Academic Fellowship from the Society for the Study of Addiction
- National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) for Mental Health at South London and Maudsley NHS Foundation Trust and King's College London - BRC
Ask authors/readers for more resources
Over the past 5 years, public interest in the potential health benefits of cannabidiol (CBD) has increased exponentially, and a wide range of over-the-counter (OTC) preparations of CBD are now available. A substantial proportion of the population appears to have used these products, yet the extent to which they are effective or safe is unclear. We reviewed the evidence for whether CBD has significant pharmacological and symptomatic effects at the doses typically found in OTC preparations. We found that most of the evidence for beneficial effects is derived from studies of pure, pharmaceutical grade CBD at relatively high doses. Relatively few studies have examined the effect of OTC CBD preparations, or of CBD at low doses. Thus, at present, there is little evidence that OTC CBD products have health benefits, and their safety has not been investigated. Controlled trials of OTC and low-dose CBD preparations are needed to resolve these issues.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available